- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02509546
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose (recommended phase II dose, RP2D) of 8-chloro-adenosine, when given as a single agent, in patients with relapsed or refractory acute myeloid leukemia. (Phase I) II. To assess tolerability and safety of 8-chloro-adenosine at each dose level by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration. (Phase I) III. To estimate the response rate and to evaluate the antitumor activity of 8-chloro-adenosine, when given as a single agent, as assessed by complete remission rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]). (Phase II)
SECONDARY OBJECTIVES:
I. To evaluate for disease response to 8-chloro-adenosine in refractory/relapsed acute myeloid leukemia (AML) on each dose level tested. (Phase I) II. To obtain estimates of remission duration and survival probabilities (overall and event-free). (Phase II) III. To obtain an estimate of the overall response rate (CR + CRi + partial response [PR]). (Phase II) IV. To summarize and evaluate toxicities by type, frequency, severity, attribution, time course and duration. (Phase II)
CLINICAL PHARMACOLOGY OBJECTIVES:
I. To describe the plasma, urinary and cellular pharmacokinetics of 8-chloro-adenosine and metabolites.
II. To determine the impact of 8-chloro-adenosine on cellular adenosine triphosphate (ATP) pool in AML blasts.
III. To assess the impact of 8-chloro-adenosine therapy on select short-lived messenger (m) ribonucleic acids (RNAs) and corresponding proteins in circulating AML blasts.
IV. To correlate clinical responses and toxicity with plasma/urine 8-chloro-adenosine level (pharmacokinetic [PK]), cellular 8-chloro-ATP (PK) and cellular ATP pool.
EXPLORATORY EX-VIVO MOLECULAR OBJECTIVES:
I. To determine the cytotoxicity of 8-chloro-adenosine toward leukemic progenitor cells in vitro.
II. To generate a preliminary pre-treatment RNA/micro RNA (miRNA) signature in leukemic progenitor cells, and explore its possible association with in vitro cytotoxicity to 8-chloro-adenosine.
III. To explore the possible association between the preliminary RNA/miRNA signature and clinical response to 8-chloro-adenosine.
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
Patients receive 8-chloro-adenosine intravenously (IV) over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days and then every 3 months for up to 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- All subjects must have the ability to understand and the willingness to sign a written informed consent
- Patients must have a life expectancy of > 3 months
- Patients must exhibit an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Patients must have a diagnosis of AML as per World Health Organization (WHO) Classification of Hematologic Neoplasms
Patients must meet one of the three treatment history criteria:
- Relapsed AML who have failed at least 1 line of salvage therapy
- De novo AML who have not achieved CR after 2 lines of therapy
- AML evolving from myelodysplastic syndrome (MDS) or myeloproliferative disorder who have failed hypomethylating agent or induction chemotherapy
- Patients who have relapsed after allogeneic hematopoietic cell transplant (HCT) are eligible if they are at least 3 months after HCT, do not have active graft vs. host disease (GVHD) and are off immunosuppression except for maintenance dose of steroids (prednisone 10 mg/day or less)
- At least 2 weeks from prior chemotherapy or radiation therapy to time of start of treatment, except for hydroxyurea or corticosteroid therapy which may be continued through cycle 1
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
- Total bilirubin =< 1.5 X ULN
- Corrected QT (QTc) =< 480 ms
- Calculated creatinine clearance (CrCl) >= 50 mL/min per 24 hour urine collection or the Cockcroft-Gault formula
- Negative serum or urine beta-human chorionic gonadotropin (beta-HCG) test (female of childbearing potential only), to be performed locally within the screening period
- Agreement by females of childbearing potential and sexually active males to use an effective method of contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for three months following duration of study participation; the effects of study treatment on a developing fetus have the potential for teratogenic or abortifacient effects; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Exclusion Criteria:
- Current or planned use of other investigational agents, or concurrent biological chemotherapy, or radiation therapy during the study treatment period
- Expected to undergo HCT within 120 days of enrollment
- Current or planned use of agents that prolong or suspected to prolong QTc
- Diagnosis of acute promyelocytic leukemia
- Active central nervous system leukemia
- Active fungal infection or bacterial sepsis
- Active peptic ulcer disease
- History of heart failure or cardiac arrhythmia
- Other active malignancy except for localized skin cancer, bladder, prostate, breast or cervical carcinoma in situ
- Pregnant women and women who are lactating; 8-chloro-adenosine is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 8-chloro-adenosine, breastfeeding should be discontinued if the mother is treated with 8-chloro-adenosine
- Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures
- Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I - 100mg/m^2 1-hour infusion
100mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
Experimental: Phase I - 200mg/m^2 1-hour infusion
200mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
Experimental: Phase I - 400mg/m^2 1-hour infusion
400mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
Experimental: Phase I - 800mg/m^2 1-hour infusion
800mg/m^2 8-chloro-adenosine administered a one-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
Experimental: Phase I - 400mg/m^2 4-hour infusion
400mg/m^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
Experimental: Phase I - 600mg/m^2 4-hour infusion
600mg/m^2 8-chloro-adenosine administered a four-hour intravenous infusion daily for first 5 days of each 28-day cycle, up to four cycles.
|
Correlative studies
Correlative studies
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado)
Time Frame: Up to 28 days following first study agent administration.
|
According to the standard 3+3 rules, where the highest DL that produced ≤ 1/6 DLTs in cycle 1 would be defined as the maximum tolerated dose (MTD).
The RP2D of 8-Cl-Ado would generally be the MTD, but it could be less than the initially calculated MTD as determined from a review of the available data and cumulative toxicities from phase 1.
|
Up to 28 days following first study agent administration.
|
Dose Limiting Toxicity (DLT)
Time Frame: Up to 28 days following first study agent administration.
|
Toxicity was graded according to the NCI-Common Terminology Criteria for Adverse Events version 4.03.
A DLT was defined as any of the following toxicities (please see the details in section of 13.2 of the protocol) that occur during cycle 1, per CTCAE version 4.03, and were considered related to the study drug.
|
Up to 28 days following first study agent administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Remission Rate (CR + CRi)
Time Frame: Up to 2 years following first study agent administration.
|
Complete remission rate (CR + CRi) based on the Döhner 2010 criteria and calculated as the percent of evaluable patients that have confirmed CR or CRi is to evaluate the antitumor activity of 8-chloro-adenosine.
|
Up to 2 years following first study agent administration.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma pharmacokinetic (PK) parameters of 8-chloro-adenosine its deaminated metabolite, 8-chloro-inosine, and its base 8-chloro-adenine
Time Frame: Course 1: pre-infusion, start of infusion, within last 15 minutes of infusion, end of infusion (EOI), 1, 3, 6-8, and 12-18 hours after infusion (day 1); pre-infusion, start of infusion, within last 15 minutes, and EOI (days 2-5)
|
Will be quantitated as continual measurement variables.
Descriptive statistics and graphical displays will be used to summarize levels of 8-chloro-adenosine and its metabolites at each time point to evaluate changes pre- and post-treatment measurement.
A pair t-test will be used to determine if there is a statistically significant change.
Summary statistics of the PK/pharmacodynamic (PD) parameters for the population will be derived from the parameters obtained from the individual patients.
|
Course 1: pre-infusion, start of infusion, within last 15 minutes of infusion, end of infusion (EOI), 1, 3, 6-8, and 12-18 hours after infusion (day 1); pre-infusion, start of infusion, within last 15 minutes, and EOI (days 2-5)
|
Cellular PK parameters of concentrations of 8-chloro-adenosine and 8-chloro-ATP in circulating leukemia cells in peripheral blood
Time Frame: Course 1: pre-infusion, start of infusion, within last 15 minutes of infusion, EOI, 1, 3, 6-8, and 12-18 hours after infusion (day 1); pre-infusion, start of infusion, within last 15 minutes, and EOI (days 2-5)
|
Will be quantitated as continual measurement variables.
Descriptive statistics and graphical displays will be used to summarize levels of 8-chloro-adenosine and its metabolites at each time point to evaluate changes pre- and post-treatment measurement.
A pair t-test will be used to determine if there is a statistically significant change.
Summary statistics of the PK/PD parameters for the population will be derived from the parameters obtained from the individual patients.
|
Course 1: pre-infusion, start of infusion, within last 15 minutes of infusion, EOI, 1, 3, 6-8, and 12-18 hours after infusion (day 1); pre-infusion, start of infusion, within last 15 minutes, and EOI (days 2-5)
|
Urine PK parameters of 8-chloro-adenosine, its deaminated metabolite, 8-chloro-Inosine, and its base 8-chloro-adenine
Time Frame: 0-8 hours, 8-16 hours, and 16-24 hours during the first 24 hours after administration on day 1
|
Will be quantitated as continual measurement variables.
Descriptive statistics and graphical displays will be used to summarize levels of 8-chloro-adenosine and its metabolites at each time point to evaluate changes pre- and post-treatment measurement.
A pair t-test will be used to determine if there is a statistically significant change.
Summary statistics of the PK/PD parameters for the population will be derived from the parameters obtained from the individual patients.
|
0-8 hours, 8-16 hours, and 16-24 hours during the first 24 hours after administration on day 1
|
Level of protein expression and protein modifications
Time Frame: Up to day 22
|
Protein level (e.g., phosphorylation, cleavage, and fatty acid modification) will be summarized descriptively using means, medians, standard deviations and ranges.
Summary statistics of the PK/PD parameters for the population will be derived from the parameters obtained from the individual patients.
|
Up to day 22
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Vinod Pullarkat, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Adenosine
Other Study ID Numbers
- 14269 (Other Identifier: City of Hope Comprehensive Cancer Center)
- 123456 (UMMashhad)
- NCI-2015-00871 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 122489
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
-
National Cancer Institute (NCI)Not yet recruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm | Acute Myeloid Leukemia Post Cytotoxic Therapy
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid LeukemiaUnited States
-
Brian DrukerAbbVie; Oregon Health and Science University; Incyte CorporationActive, not recruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Therapy-Related Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in RemissionUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With Myelodysplasia-Related ChangesUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic SyndromeUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States